Literature DB >> 6742615

Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists.

H S Stanbrook, K G Morris, I F McMurtry.   

Abstract

There exists no agreement as to the best vasodilator drug for treatment of hypoxic pulmonary hypertension. We wondered which of 3 commonly used vasodilators - verapamil, nifedipine, or hydralazine - would be the most effective in reducing and reversing the development of hypoxic pulmonary hypertension in the conscious rat. Hemodynamic studies showed that all 3 drugs inhibited the pressor response to acute hypoxia. Given for 1 month to conscious rats during exposure to intermittent hypoxia, verapamil and nifedipine reduced pulmonary hypertension when compared with hypoxic control animals, as indicated by right ventricular hypertrophy, total pulmonary resistance, and medial thickening. Hydralazine caused similar, but smaller, changes. Nifedipine, when used to reverse established hypoxic pulmonary hypertension, reduced right ventricular hypertrophy and medial thickening. Cardiac and systemic effects were negligible. These results demonstrate that the calcium channel blockers reduce the development of hypoxic pulmonary hypertension and that nifedipine partially reverses established hypertension.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6742615     DOI: 10.1164/arrd.1984.130.1.81

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  20 in total

1.  Hypoxia-induced pulmonary vascular remodeling: a model for what human disease?

Authors:  N F Voelkel; R M Tuder
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 2.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

3.  Bortezomib alleviates experimental pulmonary hypertension by regulating intracellular calcium homeostasis in PASMCs.

Authors:  Jun Zhang; Wenju Lu; Yuqin Chen; Qian Jiang; Kai Yang; Meichan Li; Ziyi Wang; Xin Duan; Lei Xu; Haiyang Tang; Dejun Sun; Jian Wang
Journal:  Am J Physiol Cell Physiol       Date:  2016-07-13       Impact factor: 4.249

4.  Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110.

Authors:  D A Handley; R G Van Valen; M K Melden; R N Saunders
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

5.  Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats.

Authors:  S W Chang; C O Feddersen; P M Henson; N F Voelkel
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

Review 6.  Can pulmonary vasodilators improve survival in cor pulmonale due to hypoxic chronic bronchitis and emphysema?

Authors:  K F Whyte; D C Flenley
Journal:  Thorax       Date:  1988-01       Impact factor: 9.139

Review 7.  Medicine and mechanisms in altitude sickness. Recommendations.

Authors:  J H Coote
Journal:  Sports Med       Date:  1995-09       Impact factor: 11.136

8.  The effect of isoproterenol on the development and recovery of hypoxic pulmonary hypertension. A structural and hemodynamic study.

Authors:  R Fried; L M Reid
Journal:  Am J Pathol       Date:  1985-10       Impact factor: 4.307

9.  Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats.

Authors:  Jian Wang; Qian Jiang; Limei Wan; Kai Yang; Yi Zhang; Yuqin Chen; Elizabeth Wang; Ning Lai; Lei Zhao; Hua Jiang; Yueqian Sun; Nanshan Zhong; Pixin Ran; Wenju Lu
Journal:  Am J Respir Cell Mol Biol       Date:  2012-10-11       Impact factor: 6.914

10.  Semotiadil inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.

Authors:  T Takahashi; T Kanda; S Imai; T Suzuki; I Kobayashi; K Murata
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.